CONTEXT: Although recent animal studies have suggested that C1q/TNF-related protein-9 (CTRP9) is more likely to be involved in the regulation of vascular function, more specifically atherosclerosis, in rodents, little is known about whether serum CTRP9 level is associated with atherosclerosis in humans. OBJECTIVE: The aim of this study was to investigate whether serum CTRP9 concentration is associated with atherosclerosis by measuring brachial ankle pulse wave velocity (baPWV) in subjects with type 2 diabetes. In addition, we examined the clinical and biochemical variables associated with serum CTRP9 concentration. DESIGN AND METHODS: We measured circulating CTRP9 and total adiponectin levels in 278 subjects (169 men and 109 women; mean age of 58.3 years) with type 2 diabetes. Measurements of baPWV were performed in all subjects. RESULTS: Serum CTRP9 concentration was positively correlated with baPWV. This correlation was significant even after adjusting for total adiponectin levels. In multiple linear regression, serum CTRP9 concentration was independently associated with increased baPWV. Female gender, higher body mass index, and homeostatic model assessment of insulin resistance were significantly associated with elevated serum CTRP9 concentration in subjects with type 2 diabetes. CONCLUSIONS: Serum CTRP9 concentration was significantly and positively associated with arterial stiffness in patients with type 2 diabetes, suggesting that CTRP9 might be important in the regulation of arterial stiffness in humans.
CONTEXT: Although recent animal studies have suggested that C1q/TNF-related protein-9 (CTRP9) is more likely to be involved in the regulation of vascular function, more specifically atherosclerosis, in rodents, little is known about whether serum CTRP9 level is associated with atherosclerosis in humans. OBJECTIVE: The aim of this study was to investigate whether serum CTRP9 concentration is associated with atherosclerosis by measuring brachial ankle pulse wave velocity (baPWV) in subjects with type 2 diabetes. In addition, we examined the clinical and biochemical variables associated with serum CTRP9 concentration. DESIGN AND METHODS: We measured circulating CTRP9 and total adiponectin levels in 278 subjects (169 men and 109 women; mean age of 58.3 years) with type 2 diabetes. Measurements of baPWV were performed in all subjects. RESULTS: Serum CTRP9 concentration was positively correlated with baPWV. This correlation was significant even after adjusting for total adiponectin levels. In multiple linear regression, serum CTRP9 concentration was independently associated with increased baPWV. Female gender, higher body mass index, and homeostatic model assessment of insulin resistance were significantly associated with elevated serum CTRP9 concentration in subjects with type 2 diabetes. CONCLUSIONS: Serum CTRP9 concentration was significantly and positively associated with arterial stiffness in patients with type 2 diabetes, suggesting that CTRP9 might be important in the regulation of arterial stiffness in humans.
Authors: Risa M Wolf; Kimberley E Steele; Leigh A Peterson; Xiange Zeng; Andrew E Jaffe; Michael A Schweitzer; Thomas H Magnuson; G William Wong Journal: J Clin Endocrinol Metab Date: 2016-03-16 Impact factor: 5.958
Authors: Risa M Wolf; Andrew E Jaffe; Susana Rodriguez; Xia Lei; Dylan C Sarver; Alexander T Straub; G William Wong; Sheela N Magge Journal: Am J Physiol Endocrinol Metab Date: 2021-04-26 Impact factor: 5.900
Authors: Chang Hee Jung; Woo Je Lee; Min Jung Lee; Yu Mi Kang; Jung Eun Jang; Jaechan Leem; Yoo La Lee; So Mi Seol; Hae Kyeong Yoon; Joong-Yeol Park Journal: Cardiovasc Diabetol Date: 2015-04-15 Impact factor: 9.951
Authors: Colleen M Dewey; Kathryn M Spitler; Jessica M Ponce; Duane D Hall; Chad E Grueter Journal: J Am Heart Assoc Date: 2016-05-31 Impact factor: 5.501